Radical excision of Barrett's esophagus and complete recovery of normal squamous epithelium

Hirohito Mori, Hideki Kobara, Kazi Rafiq, Noriko Nishiyama, Shintaro Fujihara, Maki Ayagi, Tatsuo Yachida, Kiyohito Kato, Tsutomu Masaki

INTRODUCTION

Barrett’s esophagus (BE) is a condition of the esophageal mucosa where the esophageal squamous epithelium is replaced with columnar epithelium because of prolonged reflux of gastric acid and bile acid into the esophagus. However, the definition of the esophageal gastric junction (EGJ) is different between Japan and other countries and remains controversial. In Japan, EGJ is defined as the distal limit of the lower esophageal palisade vessels, but as the proximal margin of the gastric folds (Prague criteria). The Japanese criteria may be more suitable for the definition of EGJ and for the diagnosis of endoscopic BE than other criteria[1]. Moreover, pathologically, the need to identify goblet cells in esophageal biopsies of BE is also controversial. Morphological evaluation of EGJ biopsies cannot distinguish whether the columnar epithelium comes from the distal esophagus or the proximal stomach[2,3]. There is also some controversy with regard to the definition, classification and histological findings and grading of dysplasia on BE[4]. The consensus indication for the treatment of BE are histological findings of...

Abstract

To treat Barrett’s esophagus (BE), radiofrequency ablation or cryotherapy are effective treatments for eradicating BE with dysplasia and intestinal metaplasia, and reduce the rates of Barrett’s esophageal adenocarcinoma (BAC). However, patients with BE and dysplasia or early cancer who achieved complete eradication of intestinal metaplasia, BE recurred in 5% within a year, requiring expensive endoscopic surveillances. We performed endoscopic submucosal dissection as complete radically curable treatment procedure for BE with dysplasia, intestinal metaplasia and BAC.

Core tip: Radiofrequency ablation or cryotherapy is effective for eradicating Barrett’s esophagus (BE) with dysplasia; however, it recurs in 5% in a year. Endoscopic submucosal dissection is a complete radically curable treatment procedure for BE with dysplasia and Barrett’s esophageal adenocarcinoma.

Key words: Barrett’s esophagus; Radiofrequency ablation; Cryotherapy; Endoscopic submucosal dissection; Radically curable treatment
high-grade dysplasia (HGD) by biopsies. After diagnosis of intestinal metaplasia of specific columnar epithelium and HGD, radio frequency ablation (RFA) or cryotherapy is performed because of the increased risk of Barrett’s adenocarcinoma (BAC) associated with HGD; however, the recurrence rate of BE is 5% within a year. This indicates that even patients who underwent RFA require closer endoscopic surveillance. As a complete radically curable treatment, we performed entire circumference resection by endoscopic submucosal dissection (ESD) and subsequent steroid treatment. The application and permeation with balloon dilatation were performed to prevent stenosis. We report two cases of en bloc resection of BE and BAC with ESD, in which the patients showed a complete recovery of normal squamous epithelium without recurrence.

**CASE REPORT**

**Case 1**

A 40-year-old man, whose mother died of BAC associated with BE, underwent screening with esophagogastroduodenoscopy and was diagnosed with circumferential short segment BE (SSBE), which was the same condition that caused his mother’s death (Figure 1A and C). We could not detect severe dysplasia by biopsies before ESD. However, the patient insisted upon radical resection of SSBE. Moreover, narrow band imaging magnified endoscopy revealed irregular microvascular and microsurface patterns, which prompted us to recommend ESD. The patient underwent en bloc resection with ESD because he chose to undergo excision of SSBE with ESD to prevent BAC. For the resection line, the distal side was the border of the palisade vessel and the adoral fold, and the proximal side was 10 mm proximal to the columnar epithelium. Circumferential resection was performed with ESD. On days 5, 8, 12, 15 and 20 after ESD, steroid application and permeation with balloon dilatation were performed to prevent stenosis. We used triamcinolone acetonide (TA) gel as the steroid application. The TA gel was made and applied as follows: total of 10 mL TA (100 mg) was mixed with 7.5 mL Endolubri jelly (Olympus Medical Systems, Tokyo, Japan) to make 17.5 mL of gel. Beginning at the distal side of the artificial ulcer, steroid gel was applied to the ulcer floor while pulling the scope out spirally to the proximal side of the ulcer, using a spraying tube to apply the steroid gel precisely. Subsequently, 5 min of balloon dilatation (12-15 mm in diameter) was performed immediately to allow the steroid gel to permeate into the artificial ulcer. Three months after ESD and steroid treatment, squamous epithelium without stenosis was recovered at the excision site. The site returned to normal stratified squamous epithelium, which was confirmed by a biopsy of the regenerating squamous epithelium after resection.
Case 2

A 65-year-old woman presented with a 20-year history of dysphagia associated with reflux esophagitis. BAC with HGD and severe stenosis of the lower esophagus was diagnosed (Figure 2A). The patient underwent ESD resection of BE and BAC and circumferential resection of the site of the stenosis. After ESD, steroid application and balloon dilatation were performed to prevent stenosis (Figure 2B). BAC was excised and BE was replaced with squamous epithelium (Figure 2C). The normal stratified squamous epithelium was observed at the excision site 6 mo after ESD, which was confirmed by a biopsy (Figure 2D). Narrow band imaging magnified endoscopy also showed a normal intraepithelial papillary capillary loop (IPCL type I). The patient has had no recurrence for 5 years. In addition, high-grade stenosis of the lower esophagus almost disappeared.

DISCUSSION

The cancerization rate and therapy of BE are still controversial[6,7]. Some researchers have reported lower incidences of dysplasia and BAC among patients with non-dysplastic BE, and most patients were cancer free after a long-term follow-up. Therefore, endoscopic surveillance intervals should be lengthened[8]. Others reported that the incidence of BAC in patients with BE was 30 times more frequent than in the general population[9]. Although closed endoscopic random biopsy is recommended for BE including HGD to detect BAC at an early stage, cancer detection is impossible unless BAC is at the site of biopsy[10,11]. RFA is an established treatment for BE with dysplasia. Although the short-term results of RFA have been determined, there have been concerns about recurrence of BE after RFA. It is reported that for BE treated by RFA, 56% were in complete remission after 24 mo. However, 33% of these patients had disease recurrence within the next 2 years[12,13], which is a very high recurrence rate. Therefore, we hypothesized that radical excision by ESD without recurrence and stenosis is best and most complete radically curative treatment procedure for BE with dysplasia, intestinal metaplasia and BAC. In Japan, ESD is recommend for Barrett’s esophageal cancer after accurate diagnosis using narrow band imaging with magnifying endoscopy because of its high curative rate. However, the esophagus is a narrow organ and healing of an artificial ulcer that occupies two thirds or more of the circumference of the esophagus may result in the formation of a significant stricture. Recently, several studies have demonstrated the effectiveness of local injection or oral administration of steroids for preventing strictures[14,15]. We developed and reported a new method for preventing post-ESD stricture by steroid application and
permeation with balloon dilatation[1]. The proximal side of the lower esophageal sphincter has a lumen with a relatively high expansion ability, and is resectable circumferentially without stenosis by steroid application and permeation with balloon dilatation, even if BE with HGD is subjected to circumferential resection with ESD. In the ESD procedure, recurrence does not occur because the procedure involves en bloc resection and the regenerating epithelium returns to normal squamous epithelium. Thus, ESD seems to be effective in the treatment of BE associated with HGD.

ACKNOWLEDGMENTS

We thank Dr. Makoto Oryuu for technical and editorial assistance.

REFERENCES

1. Kinjo T, Kusano C, Oda I, Gotoda T, Prague C & amp; M and Japanese criteria: shades of Barrett’s esophagus endoscopic diagnosis. J Gastroenterol 2010; 45: 1039-1044 [PMID: 20549252 DOI: 10.1037/s00535-010-0264-y]

2. Goldblum JR. Controversies in the diagnosis of Barrett esophagus and Barrett-related dysplasia: one pathologist’s perspective. Arch Pathol Lab Med 2010; 134: 1479-1484 [PMID: 20923304 DOI: 10.1043/2010-0249-RA.1]

3. Odze RD. What the gastroenterologist needs to know about the histology of Barrett’s esophagus. Curr Opin Gas troenterol 2011; 27: 389-396 [PMID: 21543798 DOI: 10.1097/MOC.0b013e32834f551]

4. Sharma P, Montgomery E. Gastrointestinal dysplasia. Pathology 2013; 45: 273-285 [PMID: 23442738 DOI: 10.1097/PAT.0b013e32835214d7]

5. Balasubramanian G, Singh M, Gupta N, Gaddam S, Gichachino M, Wani SB, Moloney B, Higbee AD, Rastogi A, Bansal A, Sharma P. Prevalence and predictors of columnar lined esophagus in gastroesophageal reflux disease (GERD) patients undergoing upper endoscopy. Am J Gastroenterol 2012; 107: 1655-1661 [PMID: 23032983 DOI: 10.1038/ajg.2012.299]

6. Orman ES, Kim HP, Bulsiewicz WJ, Cotton CC, Dellon ES, Spacek MB, Chen X, Madanick RD, Pasricha S, Shaheen NJ. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett’s esophagus with radiofrequency ablation. Am J Gastroenterol 2013; 108: 187-195, quiz 196 [PMID: 23247578 DOI: 10.1038/ajg.2012.413]

7. Mori H, Rafiq K, Kobara H, Fujihara S, Nishiyama N, Oryuu M, Suzuki Y, Masaki T. Steroid permeation into the artificial ulcer by combined steroid gel application and balloon dilatation: prevention of esophageal stricture. J Gastroenterol Hepatol 2013; 28: 999-1003 [PMID: 23425051 DOI: 10.1111/j.1440-1746.2013.07154]

8. De Palma GD. Management strategies of Barrett’s esophagus. World J Gastroenterol 2012; 18: 6216-6225 [PMID: 23180941 DOI: 10.3748/wjg.v18.i43.6216]

9. Wani S, Falk G, Hall M, Gaddam S, Wang A, Gupta N, Singh M, Singh V, Chuang KY, Boolchand V, Gavini H, Kuczynski J, Sud P, Reddymasu S, Bansal A, Rastogi A, Mathur SC, Young P, Cash B, Lieberman DA, Sampliner RE, Sharma P. Patients with nondoysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 220-227, quiz e26 [PMID: 21115133 DOI: 10.1016/j.cgh.2010.11.008]

10. Enestvedt BK, Ginsberg GG. Advances in endoluminal therapy for esophageal cancer. Gastrointest Endosc Clin N Am 2013; 23: 17-39 [PMID: 23168117 DOI: 10.1016/j.giec.2012.10.003]

11. Hoara P, Gindea C, Birla R, Mocanu A, Tavlas E, Constantinou S. The treatment of Barrett’s esophagus. J Med Life 2009; 2: 241-248 [PMID: 20112466]

12. Gupta M, Iyer PG, Lutitzke L, Gorospe EC, Abrams JA, Falk GW, Ginsberg GG, Rusted AK, Lightdale CJ, Wang TC, Fudman DI, Poneros JM, Wang KK. Recurrence of Esophageal Intestinal Metaplasia After Endoscopic Mucosal Resection and Radiofrequency Ablation of Barrett’s Esophagus: Results From a US Multicenter Consortium. Gastroenterology 2013; 145: 79-86.e1 [PMID: 23499759 DOI: 10.1053/j.gastro.2013.03.008]

13. Haidry RJ, Dunn JM, Butt MA, Burrell MG, Gupta A, Green S, Miah H, Smart HL, Bhandari P, Smith LA, Willert R, Fularton G, Morris J, Di Pietro M, Gordon C, Penman I, Barr H, Patel P, Boger P, Kapoor N, Mahon B, Hoare J, Narayanasamy R, O’Toole D, Cheong E, Direkze NC, Ang Y, Novelli M, Banks MR, Lovat LB. Radiofrequency Ablation and Endoscopic Mucosal Resection for Dysplastic Barrett’s Esophagus and Early Esophageal Adenocarcinoma: Outcomes of the UK National Hallo RFA Registry. Gastroenterology 2013; 145: 87-95 [PMID: 23542069 DOI: 10.1053/j.gastro.2013.03.045]

14. Yamaguchi N, Isomoto H, Nakayama T, Hayashi T, Nishiyama H, Ohnita K, Takushima F, Shikuwa S, Kono S, Nakao K. Usefulness of oral prednisolone in the treatment of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. Gas trointest Endosc 2011; 73: 1115-1121 [PMID: 21492854 DOI: 10.1016/j.gie.2011.02.005]

15. Hashimoto S, Kobayashi M, Takeuchi M, Sato Y, Narisawa R, Aoyagi Y. The efficacy of endoscopic triamcinolone injection for the prevention of esophageal stricture after endoscopic submucosal dissection. Gastrointest Endosc 2011; 74: 1389-1395 [PMID: 22136792 DOI: 10.1016/j.gie.2011.07.070].
